Filters
Price
Category
Peptides
Administration
Dosage
Research Focus
Brand
Rating
Status
Best Sellers
-
GHK-CU (Capsules)
£44.99 – £48.99Price range: £44.99 through £48.99mg
-
Advanced Ghk-Cu Spray
£24.99
-
Cagrilintide
£44.99 – £58.99Price range: £44.99 through £58.99
-
Tirzepatide (Pen)
£54.99 – £74.99Price range: £54.99 through £74.99
-
Retatrutide (Vial)
£58.99 – £92.99Price range: £58.99 through £92.99
Showing all 3 results
Showing all 3 results
CJC-1295 (No DAC)
£32.99 – £48.99Price range: £32.99 through £48.99CJC-1295 (No DAC)
Hormonal — GHRH Analogue CJC-1295 is a synthetic GHRH analogue. The no-DAC variant produces short, pulsatile GH release closely mimicking natural physiology and is commonly combined with Ipamorelin for synergistic effect across the GH axis. Target: GHRH receptor Variant: No-DAC (short-acting) Half-Life: ~30 min (no DAC)
CJC-1295 (With DAC)
£36.99 – £45.99Price range: £36.99 through £45.99CJC-1295 (With DAC)
Hormonal — GHRH Analogue CJC-1295 is a synthetic GHRH analogue. The DAC (Drug Affinity Complex) variant binds circulating albumin, extending its half-life to several days for sustained growth-hormone elevation rather than the short pulsatile release of the no-DAC form. Target: GHRH receptor Variant: With DAC (long-acting) Half-Life: ~6–8 days
Tesamorelin
£22.99 – £90.99Price range: £22.99 through £90.99Tesamorelin
Hormonal — GHRH Analogue Tesamorelin
An FDA-approved synthetic GHRH analogue (Egrifta®) for the reduction of excess visceral adipose tissue in HIV-associated lipodystrophy.
It is unique among GH-axis peptides in having genuine regulatory approval, and its clinical data provides high-quality evidence for its mechanism and effects on body composition.
- Approval: FDA 2010 (Egrifta®)
- Indication: HIV lipodystrophy — visceral fat
- Half-Life: ~26 minutes










